Neutrophil elastase as a diagnostic marker and therapeutic target in colorectal cancers

Ai Sheng Ho, Chien Hsin Chen, Chun Chia Cheng, Chia Chi Wang, Hua Ching Lin, Tsai Yueh Luo, Gi Shih Lien, Jungshan Chang

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Neutrophil elastase (NE), a serine protease secreted by neutrophils, contributes to the progression of cancers to enhance tumor invasion and metastasis. It has been well reported that the regions surrounding the colorectal cancerous tissues usually are decorated with increased accumulation or aggregation of neutrophils coupled with a higher deposition/expression of NE. Therefore, we hypothesized that an increased expressional level of NE in patients with colorectal cancer (CRC) may represent as one of putative biomarkers for CRC. The aim of this study was to evaluate and assure our hypothesis by measurements of the expressional level of NE in the sera and tissues from CRC patients. Moreover, we also proposed a potential therapeutic strategy by blocking enzymatic activity of NE using sivelestat to inhibit the progression of tumor developments. The infiltrated numbers of neutrophils from specimen tissues of CRC patients, and the secreted forms of NE in the sera were quantitatively measured and compared. To evaluate the serum NE as one of putative biomarkers of CRC patients, the receiver operating characteristic (ROC) curve was made to determine the cut-off value of NE in sera for assurance of CRC diagnosis. To evaluate NE as therapeutic target for CRC, sivelestat, a NE inhibitor, was used and administrated into the CRC xenografts. NE expression level coupled with tumor volume were measured and compared between the control and sivelestat-treated xenografts. We found that more infiltrated neutrophils and an increased NE expression were detected in the cancerous tissues compared to the normal tissues. The serum NE concentration in CRC patients was statistically higher than that in the healthy controls (0.56±0.08 μg/ml vs. 0.22±0.03μg/ml) (p

Original languageEnglish
Pages (from-to)473-480
Number of pages8
JournalOncotarget
Volume5
Issue number2
Publication statusPublished - 2014

Fingerprint

Leukocyte Elastase
Colorectal Neoplasms
Neutrophils
Therapeutics
Serum
Heterografts
Secretory Proteinase Inhibitory Proteins
Biomarkers
Neoplasms
Serine Proteases
Tumor Burden
ROC Curve

Keywords

  • Biomarker
  • Colorectal cancer
  • Neutrophil elastase

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Ho, A. S., Chen, C. H., Cheng, C. C., Wang, C. C., Lin, H. C., Luo, T. Y., ... Chang, J. (2014). Neutrophil elastase as a diagnostic marker and therapeutic target in colorectal cancers. Oncotarget, 5(2), 473-480.

Neutrophil elastase as a diagnostic marker and therapeutic target in colorectal cancers. / Ho, Ai Sheng; Chen, Chien Hsin; Cheng, Chun Chia; Wang, Chia Chi; Lin, Hua Ching; Luo, Tsai Yueh; Lien, Gi Shih; Chang, Jungshan.

In: Oncotarget, Vol. 5, No. 2, 2014, p. 473-480.

Research output: Contribution to journalArticle

Ho, AS, Chen, CH, Cheng, CC, Wang, CC, Lin, HC, Luo, TY, Lien, GS & Chang, J 2014, 'Neutrophil elastase as a diagnostic marker and therapeutic target in colorectal cancers', Oncotarget, vol. 5, no. 2, pp. 473-480.
Ho AS, Chen CH, Cheng CC, Wang CC, Lin HC, Luo TY et al. Neutrophil elastase as a diagnostic marker and therapeutic target in colorectal cancers. Oncotarget. 2014;5(2):473-480.
Ho, Ai Sheng ; Chen, Chien Hsin ; Cheng, Chun Chia ; Wang, Chia Chi ; Lin, Hua Ching ; Luo, Tsai Yueh ; Lien, Gi Shih ; Chang, Jungshan. / Neutrophil elastase as a diagnostic marker and therapeutic target in colorectal cancers. In: Oncotarget. 2014 ; Vol. 5, No. 2. pp. 473-480.
@article{acfe655d122c4e79b181502f497ea9c3,
title = "Neutrophil elastase as a diagnostic marker and therapeutic target in colorectal cancers",
abstract = "Neutrophil elastase (NE), a serine protease secreted by neutrophils, contributes to the progression of cancers to enhance tumor invasion and metastasis. It has been well reported that the regions surrounding the colorectal cancerous tissues usually are decorated with increased accumulation or aggregation of neutrophils coupled with a higher deposition/expression of NE. Therefore, we hypothesized that an increased expressional level of NE in patients with colorectal cancer (CRC) may represent as one of putative biomarkers for CRC. The aim of this study was to evaluate and assure our hypothesis by measurements of the expressional level of NE in the sera and tissues from CRC patients. Moreover, we also proposed a potential therapeutic strategy by blocking enzymatic activity of NE using sivelestat to inhibit the progression of tumor developments. The infiltrated numbers of neutrophils from specimen tissues of CRC patients, and the secreted forms of NE in the sera were quantitatively measured and compared. To evaluate the serum NE as one of putative biomarkers of CRC patients, the receiver operating characteristic (ROC) curve was made to determine the cut-off value of NE in sera for assurance of CRC diagnosis. To evaluate NE as therapeutic target for CRC, sivelestat, a NE inhibitor, was used and administrated into the CRC xenografts. NE expression level coupled with tumor volume were measured and compared between the control and sivelestat-treated xenografts. We found that more infiltrated neutrophils and an increased NE expression were detected in the cancerous tissues compared to the normal tissues. The serum NE concentration in CRC patients was statistically higher than that in the healthy controls (0.56±0.08 μg/ml vs. 0.22±0.03μg/ml) (p",
keywords = "Biomarker, Colorectal cancer, Neutrophil elastase",
author = "Ho, {Ai Sheng} and Chen, {Chien Hsin} and Cheng, {Chun Chia} and Wang, {Chia Chi} and Lin, {Hua Ching} and Luo, {Tsai Yueh} and Lien, {Gi Shih} and Jungshan Chang",
year = "2014",
language = "English",
volume = "5",
pages = "473--480",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "2",

}

TY - JOUR

T1 - Neutrophil elastase as a diagnostic marker and therapeutic target in colorectal cancers

AU - Ho, Ai Sheng

AU - Chen, Chien Hsin

AU - Cheng, Chun Chia

AU - Wang, Chia Chi

AU - Lin, Hua Ching

AU - Luo, Tsai Yueh

AU - Lien, Gi Shih

AU - Chang, Jungshan

PY - 2014

Y1 - 2014

N2 - Neutrophil elastase (NE), a serine protease secreted by neutrophils, contributes to the progression of cancers to enhance tumor invasion and metastasis. It has been well reported that the regions surrounding the colorectal cancerous tissues usually are decorated with increased accumulation or aggregation of neutrophils coupled with a higher deposition/expression of NE. Therefore, we hypothesized that an increased expressional level of NE in patients with colorectal cancer (CRC) may represent as one of putative biomarkers for CRC. The aim of this study was to evaluate and assure our hypothesis by measurements of the expressional level of NE in the sera and tissues from CRC patients. Moreover, we also proposed a potential therapeutic strategy by blocking enzymatic activity of NE using sivelestat to inhibit the progression of tumor developments. The infiltrated numbers of neutrophils from specimen tissues of CRC patients, and the secreted forms of NE in the sera were quantitatively measured and compared. To evaluate the serum NE as one of putative biomarkers of CRC patients, the receiver operating characteristic (ROC) curve was made to determine the cut-off value of NE in sera for assurance of CRC diagnosis. To evaluate NE as therapeutic target for CRC, sivelestat, a NE inhibitor, was used and administrated into the CRC xenografts. NE expression level coupled with tumor volume were measured and compared between the control and sivelestat-treated xenografts. We found that more infiltrated neutrophils and an increased NE expression were detected in the cancerous tissues compared to the normal tissues. The serum NE concentration in CRC patients was statistically higher than that in the healthy controls (0.56±0.08 μg/ml vs. 0.22±0.03μg/ml) (p

AB - Neutrophil elastase (NE), a serine protease secreted by neutrophils, contributes to the progression of cancers to enhance tumor invasion and metastasis. It has been well reported that the regions surrounding the colorectal cancerous tissues usually are decorated with increased accumulation or aggregation of neutrophils coupled with a higher deposition/expression of NE. Therefore, we hypothesized that an increased expressional level of NE in patients with colorectal cancer (CRC) may represent as one of putative biomarkers for CRC. The aim of this study was to evaluate and assure our hypothesis by measurements of the expressional level of NE in the sera and tissues from CRC patients. Moreover, we also proposed a potential therapeutic strategy by blocking enzymatic activity of NE using sivelestat to inhibit the progression of tumor developments. The infiltrated numbers of neutrophils from specimen tissues of CRC patients, and the secreted forms of NE in the sera were quantitatively measured and compared. To evaluate the serum NE as one of putative biomarkers of CRC patients, the receiver operating characteristic (ROC) curve was made to determine the cut-off value of NE in sera for assurance of CRC diagnosis. To evaluate NE as therapeutic target for CRC, sivelestat, a NE inhibitor, was used and administrated into the CRC xenografts. NE expression level coupled with tumor volume were measured and compared between the control and sivelestat-treated xenografts. We found that more infiltrated neutrophils and an increased NE expression were detected in the cancerous tissues compared to the normal tissues. The serum NE concentration in CRC patients was statistically higher than that in the healthy controls (0.56±0.08 μg/ml vs. 0.22±0.03μg/ml) (p

KW - Biomarker

KW - Colorectal cancer

KW - Neutrophil elastase

UR - http://www.scopus.com/inward/record.url?scp=84896706728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896706728&partnerID=8YFLogxK

M3 - Article

C2 - 24457622

AN - SCOPUS:84896706728

VL - 5

SP - 473

EP - 480

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 2

ER -